Temsirolimus, mTOR Inhibitor, Inhibits Progression of Malignant Pleural Mesothelioma in Vitro.

Research Project

Project/Area Number	21791316
Research Category	Grant-in-Aid for Young Scientists (B)
Allocation Type	Single-year Grants
Research Field	Thoracic surgery
Research Institution	Kanazawa University
Principal Investigator	TAMURA Masaya Kanazawa University, 附属病院, 助教 (10397185)
Project Period (FY)	2009 – 2010
Project Status	Completed (Fiscal Year 2010)
Budget Amount *help	¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000) Fiscal Year 2010: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000) Fiscal Year 2009: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Keywords	悪性胸膜中皮腫 / 分子標的治療 / PI3K-AKT-mTOR経路 / 悪性胸膜皮腫 / mTOR
Research Abstract	The results suggest the therapeutic efficacy of temsirolimus against MPM in vitro. And it is expected that temsirolimus inhibits MPM growth not only by anticancer effect but by antangiogenic effect in vivo.